WHO calls for price cut on drug for Covid-linked black fungus disease

This comes amid a sharp rise in cases of black fungus infections among Covid-19 patients in India and Nepal

Black fungus

A doctor checks a patient for black fungus (Photo: PTI)

IANS London
Amid a sharp rise in cases of black fungus infections among Covid-19 patients in India and Nepal, the World Health Organisation (WHO) has on Thursday called on to lower the prices of the drug used to treat the condition, media reports said.
Developed by California-based drugmaker Gilead Sciences, AmBisome is a lipid-based amphotericin, used to treat the black fungus infections, which starts in the nose and quickly spreads to the eyes and brain. The WHO has urged the company to lower its prices as well as boost supplies to curb the rapidly rising cases in South Asia, the Financial Times reported.
"An immediate strategy for broadening supply and improving affordability of lipid-based amphotericin is to integrate it into the existing Covid-19 response and for Gilead to extend their existing lower pricing arrangement to Covid patients," Who's Assistant Director General for access to medicines, Mariangela Simao, was quoted as saying.
Last month, Medecins Sans Frontieres (MSF) and experts at Yale and Georgetown universities in the US had sent an open letter sent to Gilead stating that the it takes between 150 and 300 vials of the drug to treat a single patient, and a vial can cost up to $69 in India.
Gilead told the FT that in India the price of the drug and the terms of supply are negotiated by the US company Viatris, which stated the drug was "complex" and "involves an exceptionally long cycle time to produce" and it is even more critical due to the sudden rise in demand".
"We will continue to partner with all stakeholders and the government of India for the ongoing efforts to accelerate access to critical medicines for patients with Covid-19 in India," Viatris was quoted as saying.
Meanwhile, in May, Zydus and TLC, a specialty pharmaceutical company in Taiwan, signed a license supply and commercialisation agreement to commercialise AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India.

Also Read

US eager to involve Indian investigators in clinical trials on Covid: Fauci

What is mucormycosis, the deadly fungal infection among Covid patients

Explained: How politics, Covid-19 pandemic are taking a toll on Nepal

Zydus Cadila, Taiwan's TLC ink pact to market black fungus drug in India

AstraZeneca updates Covid-19 vaccine efficacy rate to 76%

Delhi's cloud-based health project likely to be out by March next year: CM

Treatment for people suffering from Covid vaccine-related blood clots found

Prime Minister Modi to address doctors on National Doctors' Day on July 1

AstraZeneca partners with Docon to digitise 1,000 clinics across India

Investment low in pvt healthcare, stimulus may be game-changer: V K Paul

AmphoTLC is the first and only complex generic drug to have achieved bioequivalence to Gilead's AmBisome, proving its sameness to the safest form of amphotericin B in the world.
With the surge of infections in India, the Central Drugs Standard Control Organization (CDSCO) of India also granted approval to Amphotericin B Liposome for Injection 50mg or AmphoTLC for immediate importation as per approved usage and indication.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Jul 01 2021 | 6:44 PM IST

Explore News